ID: 72026 I Dec 2019 I Global I 310 pages I MGI-6
ID: 72026 I Dec 2019 I Global I 310 pages I ;Allied Market Research
The global gene therapy market was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient’s cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market. The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period. The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. KEY MARKET BENEFITS FOR STAKEHOLDERS • This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities. • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry. • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning. • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market. KEY MARKET SEGMENTS By Vector Type • Viral vector o Retroviruses o Lentiviruses o Adenoviruses o Adeno Associated Virus o Herpes Simplex Virus o Poxvirus o Vaccinia Virus o Others • Non-viral vector o Naked/Plasmid Vectors o Gene Gun o Electroporation o Lipofection o Others By Gene Type • Antigen • Cytokine • Tumor Suppressor • Suicide • Deficiency • Growth factors • Receptors • Others By Application • Oncological Disorders • Rare Diseases • Cardiovascular Diseases • Neurological Disorders • Infectious disease • Other Diseases By Region • North America o U.S. o Canada o Mexico • Europe o Germany o UK o France o Spain o Italy o Rest of Europe • Asia-Pacific o Japan o China o Australia o India o South Korea o Rest of Asia-Pacific • LAMEA o Brazil o South Africa o Saudi Arabia o Rest of LAMEA KEY PLAYERS PROFILED • Adaptimmune Therapeutics Plc. • Anchiano Therapeutics Ltd. • Achieve Life Sciences, Inc. • Adverum Biotechnologies, Inc. • Abeona Therapeutics Inc. • Applied Genetic Technologies Corporation • Arbutus Biopharma Corporation, • Audentes Therapeutics, Inc. • AveXis, Inc. • Bluebird Bio, Inc. • Celgene Corporation • CRISPR Therapeutics AG • Editas Medicine, Inc. • Editas Medicine, Inc. • GlaxoSmithKline Plc. • Intellia Therapeutics, Inc. • Merck & Co., Inc. • Novartis AG • REGENXBIO Inc. • Spark Therapeutics, Inc. • Sangamo Therapeutics, Inc. • Uniqure N. V. Voyager Therapeutics, Inc• The other players of the gene therapy market include (companies not profiled in the report): • Amgen • Epeius Biotechnologies • Sanofi • Juno Therapeutics • Advantagene
Chapter 1: Introduction 1.1. Report Description 1.2. Key Benefits 1.3. Key Market Segments 1.4. Research Methodology 1.4.1. Secondary Research 1.4.2. Primary Research 1.4.3. Analyst Tools And Models Chapter 2: Executive Summary 2.1. Cxo Perspective Chapter 3: Market Overview 3.1. Market Definition And Scope 3.2. Key Findings 3.2.1. Top Investment Pockets 3.2.2. Top Winning Strategies 3.3. Top Player Positioning, 2018 3.4. Porter’S Five Forces Analysis 3.5. Market Dynamics 3.5.1. Drivers 3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy 3.5.1.2. Increase In Prevalence of Cancer 3.5.1.3. Growth In Awareness Regarding Gene Therapy 3.5.2. Restraints 3.5.2.1. High Cost Associated With Gene Therapies 3.5.2.2. Unwanted Immune Responses 3.5.3. Opportunities 3.5.3.1. Untapped Potential For Emerging Markets Chapter 4: Gene Therapy Market, By Vector Type 4.1. Overview 4.1.1. Market Size And Forecast 4.2. Viral Vectors 4.2.1. Key Market Trends, Growth Factors, And Opportunities 4.2.2. Market Size And Forecast, By Region 4.2.3. Market Size And Forecast, By Type 4.2.4. Market Size And Forecast, By Country 4.2.5. Adenovirus 4.2.6. Lentivirus 4.2.7. Retrovirus 4.2.8. Adeno-Associated Virus 4.2.9. Herpes Simplex Virus 4.2.10. Poxvirus 4.2.11. Vaccinia Virus 4.2.12. Others 4.3. Non-Viral Techniques 4.3.1. Key Market Trends, Growth Factors, And Opportunities 4.3.2. Market Size And Forecast, By Region 4.3.3. Market Size And Forecast, By Type 4.3.4. Market Size And Forecast, By Country 4.3.5. Naked Plasmid Vector 4.3.6. Gene Gun 4.3.7. Electroporation 4.3.8. Lipofection 4.3.9. Others Chapter 5: Gene Therapy Market, By Gene Type 5.1. Overview 5.1.1. Market Size And Forecast, Type 5.2. Antigen 5.2.1. Market Size And Forecast 5.2.2. Market Size And Forecast, By Country 5.3. Cytokine 5.3.1. Market Size And Forecast 5.3.2. Market Size And Forecast, By Country 5.4. Tumor Suppressor 5.4.1. Market Size And Forecast, By Region 5.4.2. Market Size And Forecast, By Country 5.5. Suicide Gene 5.5.1. Market Size And Forecast 5.5.2. Market Size And Forecast, By Country 5.6. Deficiency 5.6.1. Market Size And Forecast, By Region 5.6.2. Market Size And Forecast, By Country 5.7. Growth Factors 5.7.1. Market Size And Forecast, By Region 5.7.2. Market Size And Forecast, By Country 5.8. Receptors 5.8.1. Market Size And Forecast, By Region 5.8.2. Market Size And Forecast, By Country 5.9. Others 5.9.1. Market Size And Forecast, By Region 5.9.2. Market Size And Forecast, By Country Chapter 6: Gene Therapy Market, By Application 6.1. Overview 6.1.1. Market Size And Forecast, By Application 6.2. Oncological Disorders 6.2.1. Market Size And Forecast, By Region 6.2.2. Market Size And Forecast, By Country 6.3. Rare Diseases 6.3.1. Market Size And Forecast, By Region 6.3.2. Market Size And Forecast, By Country 6.4. Cardiovascular Diseases 6.4.1. Market Size And Forecast, By Region 6.4.2. Market Size And Forecast, By Country 6.5. Neurological Disorders 6.5.1. Market Size And Forecast 6.5.2. Market Size And Forecast, By Country 6.6. Infectious Diseases 6.6.1. Market Size And Forecast, By Region 6.6.2. Market Size And Forecast, By Country 6.7. Other Diseases 6.7.1. Market Size And Forecast 6.7.2. Market Size And Forecast, By Country Chapter 7: Gene Therapy Market, By Region 7.1. Overview 7.1.1. Market Size And Forecast 7.2. North America 7.2.1. Key Market Trends, Growth Factors, And Opportunities 7.2.2. Market Size And Forecast, By Country 7.2.3. Market Size And Forecast, By Vector Type 7.2.4. Market Size And Forecast, By Gene Type 7.2.5. Market Size And Forecast, By Application 7.2.5.1. U.S. Market Size And Forecast, By Vector Type 7.2.5.2. U.S. Market Size And Forecast, By Gene Type 7.2.5.3. U.S. Market Size And Forecast, By Application 7.2.5.4. Canada Market Size And Forecast, By Vector Type 7.2.5.5. Canada Market Size And Forecast, By Gene Type 7.2.5.6. Canada Market Size And Forecast, By Application 7.2.5.7. Mexico Market Size And Forecast, By Vector Type 7.2.5.8. Mexico Market Size And Forecast, By Gene Type 7.2.5.9. Mexico Market Size And Forecast, By Application 7.3. Europe 7.3.1. Key Market Trends, Growth Factors, And Opportunities 7.3.2. Market Size And Forecast, By Country 7.3.3. Market Size And Forecast, By Vector Type 7.3.4. Market Size And Forecast, By Gene Type 7.3.5. Market Size And Forecast, By Application 7.3.5.1. Germany Market Size And Forecast, By Vector Type 7.3.5.2. Germany Market Size And Forecast, By Gene Type 7.3.5.3. Germany Market Size And Forecast, By Application 7.3.5.4. France Market Size And Forecast, By Vector Type 7.3.5.5. France Market Size And Forecast, By Gene Type 7.3.5.6. France Market Size And Forecast, By Application 7.3.5.7. Uk Market Size And Forecast, By Vector Type 7.3.5.8. Uk Market Size And Forecast, By Gene Type 7.3.5.9. Uk Market Size And Forecast, By Application 7.3.5.10. Italy Market Size And Forecast, By Vector Type 7.3.5.11. Italy Market Size And Forecast, By Gene Type 7.3.5.12. Italy Market Size And Forecast, By Application 7.3.5.13. Spain Market Size And Forecast, By Vector Type 7.3.5.14. Spain Market Size And Forecast, By Gene Type 7.3.5.15. Spain Market Size And Forecast, By Application 7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type 7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type 7.3.5.18. Rest of Europe Market Size And Forecast, By Application 7.4. Asia-Pacific 7.4.1. Key Market Trends, Growth Factors, And Opportunities 7.4.2. Market Size And Forecast, By Country 7.4.3. Market Size And Forecast, By Vector Type 7.4.4. Market Size And Forecast, By Gene Type 7.4.5. Market Size And Forecast, By Application 7.4.5.1. Japan Market Size And Forecast, By Vector Type 7.4.5.2. Japan Market Size And Forecast, By Gene Type 7.4.5.3. Japan Market Size And Forecast, By Application 7.4.5.4. China Market Size And Forecast, By Vector Type 7.4.5.5. China Market Size And Forecast, By Gene Type 7.4.5.6. China Market Size And Forecast, By Application 7.4.5.7. India Market Size And Forecast, By Vector Type 7.4.5.8. India Market Size And Forecast, By Gene Type 7.4.5.9. India Market Size And Forecast, By Application 7.4.5.10. South Korea Market Size And Forecast, By Vector Type 7.4.5.11. South Korea Market Size And Forecast, By Gene Type 7.4.5.12. South Korea Market Size And Forecast, By Application 7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type 7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type 7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application 7.5. Lamea 7.5.1. Key Market Trends, Growth Factors, And Opportunities 7.5.2. Market Size And Forecast, By Country 7.5.3. Market Size And Forecast, By Vector Type 7.5.4. Market Size And Forecast, By Gene Type 7.5.5. Market Size And Forecast, By Application 7.5.5.1. Brazil Market Size And Forecast, By Vector Type 7.5.5.2. Brazil Market Size And Forecast, By Gene Type 7.5.5.3. Brazil Market Size And Forecast, By Application 7.5.5.4. South Africa Market Size And Forecast, By Vector Type 7.5.5.5. South Africa Market Size And Forecast, By Gene Type 7.5.5.6. South Africa Market Size And Forecast, By Application 7.5.5.7. Rest of Lamea Market Size And Forecast, By Vector Type 7.5.5.8. Rest of Lamea Market Size And Forecast, By Gene Type 7.5.5.9. Rest of Lamea Market Size And Forecast, By Application Chapter 8: Company Profile 8.1. Adaptimmune Therapeutics Plc. 8.1.1. Company Overview 8.1.2. Company Snapshot 8.1.3. Operating Business Segments 8.1.4. Product Portfolio 8.1.5. Business Performance 8.1.6. Key Strategic Moves And Developments 8.2. Anchiano Therapeutics Ltd. 8.2.1. Company Overview 8.2.2. Company Snapshot 8.2.3. Operating Business Segments 8.2.4. Product Portfolio 8.3. Achieve Life Sciences, Inc. 8.3.1. Company Overview 8.3.2. Company Snapshot 8.3.3. Operating Business Segments 8.3.4. Product Portfolio 8.3.5. Key Strategic Moves And Developments 8.4. Adverum Biotechnologies, Inc. 8.4.1. Company Overview 8.4.2. Company Snapshot 8.4.3. Operating Business Segments 8.4.4. Product Portfolio 8.4.5. Key Strategic Moves And Developments 8.5. Abeona Therapeutics Inc. 8.5.1. Company Overview 8.5.2. Company Snapshot 8.5.3. Operating Business Segments 8.5.4. Product Portfolio 8.5.5. Business Performance 8.5.6. Key Strategic Moves And Developments 8.6. Applied Genetic Technologies Corporation 8.6.1. Company Overview 8.6.2. Company Snapshot 8.6.3. Operating Business Segments 8.6.4. Product Portfolio 8.6.5. Business Performance 8.6.6. Key Strategic Moves And Developments 8.7. Arbutus Biopharma Corporation 8.7.1. Company Overview 8.7.2. Company Snapshot 8.7.3. Product Portfolio 8.7.4. Business Performance 8.7.5. Key Strategic Moves And Developments 8.8. Audentes Therapeutics Inc. 8.8.1. Company Overview 8.8.2. Company Snapshot 8.8.3. Product Portfolio 8.8.4. Key Strategic Moves And Developments 8.9. Avexis Inc. 8.9.1. Company Overview 8.9.2. Company Snapshot 8.9.3. Product Portfolio 8.9.4. Key Strategic Moves And Developments 8.10. Bluebird Bio, Inc. 8.10.1. Company Overview 8.10.2. Company Snapshot 8.10.3. Operating Business Segments 8.10.4. Product Portfolio 8.10.5. Business Performance 8.10.6. Key Strategic Moves And Developments 8.11. Celgene Corporation 8.11.1. Company Overview 8.11.2. Company Snapshot 8.11.3. Operating Business Segments 8.11.4. Product Portfolio 8.11.5. Business Performance 8.11.6. Key Strategic Moves And Developments 8.12. Crispr Therapeutics Ag 8.12.1. Company Overview 8.12.2. Company Snapshot 8.12.3. Product Portfolio 8.12.4. Business Performance 8.12.5. Key Strategic Moves And Developments 8.13. Editas Medicine, Inc. 8.13.1. Company Overview 8.13.2. Company Snapshot 8.13.3. Operating Business Segments 8.13.4. Product Portfolio 8.13.5. Business Performance 8.13.6. Key Strategic Moves And Developments 8.14. Gilead Sciences, Inc. 8.14.1. Company Overview 8.14.2. Company Snapshot 8.14.3. Operating Business Segments 8.14.4. Product Portfolio 8.14.5. Business Performance 8.14.6. Key Strategic Moves And Developments 8.15. Glaxosmithkline Plc 8.15.1. Company Overview 8.15.2. Company Snapshot 8.15.3. Operating Business Segments 8.15.4. Product Portfolio 8.15.5. Business Performance 8.15.6. Key Strategic Moves And Developments 8.16. Intellia Therapeutics Inc. 8.16.1. Company Overview 8.16.2. Company Snapshot 8.16.3. Operating Business Segments 8.16.4. Product Portfolio 8.16.5. Business Performance 8.16.6. Key Strategic Moves And Developments 8.17. Merck & Co., Inc. 8.17.1. Company Overview 8.17.2. Company Snapshot 8.17.3. Operating Business Segments 8.17.4. Product Portfolio 8.17.5. Business Performance 8.17.6. Key Strategic Moves And Developments 8.18. Novartis Ag 8.18.1. Company Overview 8.18.2. Company Snapshot 8.18.3. Operating Business Segments 8.18.4. Product Portfolio 8.18.5. Business Performance 8.18.6. Key Strategic Moves And Developments 8.19. Regenxbio, Inc. 8.19.1. Company Overview 8.19.2. Company Snapshot 8.19.3. Product Portfolio 8.19.4. Business Performance 8.19.5. Key Strategic Moves And Developments 8.20. Spark Therapeutics, Inc. 8.20.1. Company Overview 8.20.2. Company Snapshot 8.20.3. Operating Business Segments 8.20.4. Product Portfolio 8.20.5. Business Performance 8.20.6. Key Strategic Moves And Developments 8.21. Sangamo Therapeutics, Inc. 8.21.1. Company Overview 8.21.2. Company Snapshot 8.21.3. Operating Business Segments 8.21.4. Product Portfolio 8.21.5. Business Performance 8.21.6. Key Strategic Moves And Developments 8.22. Uniqure N. V. 8.22.1. Company Overview 8.22.2. Company Snapshot 8.22.3. Operation Segments 8.22.4. Product Portfolio 8.22.5. Business Performance 8.22.6. Key Strategic Moves And Developments 8.23. Voyager Therapeutics, Inc. 8.23.1. Company Overview 8.23.2. Company Snapshot 8.23.3. Operating Business Segments 8.23.4. Product Portfolio 8.23.5. Business Performance 8.23.6. Key Strategic Moves And Developments
List of Tables Table 01. Late-Stage Clinical Data Events of Gene Therpy Table 02. Gene Therapy Pipeline Volume, Preclinical Through Pre-Registration Phase, 1995–2018 Table 03. Global Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 04. Global Gene Therapy Market For Viral Vectors, By Region, 2018–2026 ($Million) Table 05. Global Gene Therapy Market For Viral Vectors, By Type, 2018–2026 ($Million) Table 06. Gene Therapy Market For Non-Viral Vectors, By Region, 2018–2026 ($Million) Table 07. Global Gene Therapy Market For Non-Viral Vectors, By Type, 2018–2026 ($Million) Table 08. Global Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 09. Antigen Gene Therapy Market, By Region, 2018–2026 ($Million) Table 10. Cytokine Gene Therapy Market, By Region, 2018–2026 ($Million) Table 11. Tumor Suppressor Gene Therapy Market, By Region, 2018–2026 ($Million) Table 12. Suicide Gene Therapy Market, By Region, 2018–2026 ($Million) Table 13. Deficiency Gene Therapy Market, By Region, 2018–2026 ($Million) Table 14. Growth Factors Gene Therapy Market, By Region, 2018–2026 ($Million) Table 15. Receptors Gene Therapy Market, By Region, 2018–2026 ($Million) Table 16. Gene Therapy Market For Other Gene Types, By Region, 2018–2026 ($Million) Table 17. Global Gene Therapy Market, By Application, 2018–2026 ($Million) Table 18. Gene Therapy Market For Oncological Disorders, By Region, 2018–2026 ($Million) Table 19. Gene Therapy Market For Rare Diseases, By Region, 2018–2026 ($Million) Table 20. Gene Therapy Market For Cardiovascular Diseases, By Region, 2018–2026 ($Million) Table 21. Gene Therapy Market For Neurological Disorders, By Region, 2018–2026 ($Million) Table 22. Gene Therapy Market For Infectious Diseases, By Region, 2018–2026 ($Million) Table 23. Gene Therapy Market For Other Diseases, By Region, 2018–2026 ($Million) Table 24. Gene Therapy Market, By Region, 2018-2026 ($Million) Table 25. North America Gene Therapy Market, By Country, 2018–2026 ($Million) Table 26. North America Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 27. North America Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 28. North America Gene Therapy Market, By Application, 2018–2026 ($Million) Table 29. U.S. Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 30. U.S. Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 31. U.S. Gene Therapy Market, By Application, 2018–2026 ($Million) Table 32. Canada Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 33. Canada Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 34. Canada Gene Therapy Market, By Application, 2018–2026 ($Million) Table 35. Mexico Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 36. Mexico Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 37. Mexico Gene Therapy Market, By Application, 2018–2026 ($Million) Table 38. Europe Gene Therapy Market, By Country, 2018–2026 ($Million) Table 39. Europe Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 40. Europe Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 41. Europe Gene Therapy Market, By Application, 2018–2026 ($Million) Table 42. Germany Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 43. Germany Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 44. Germany Gene Therapy Market, By Application, 2018–2026 ($Million) Table 45. France Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 46. France Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 47. France Gene Therapy Market, By Application, 2018–2026 ($Million) Table 48. Uk Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 49. Uk Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 50. Uk Gene Therapy Market, By Application, 2018–2026 ($Million) Table 51. Italy Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 52. Italy Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 53. Italy Gene Therapy Market, By Application, 2018–2026 ($Million) Table 54. Spain Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 55. Spain Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 56. Spain Gene Therapy Market, By Application, 2018–2026 ($Million) Table 57. Rest of Europe Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 58. Rest of Europe Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 59. Rest of Europe Gene Therapy Market, By Application, 2018–2026 ($Million) Table 60. Asia-Pacific Gene Therapy Market, By Country, 2018–2026 ($Million) Table 61. Asia-Pacific Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 62. Asia-Pacific Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 63. Asia-Pacific Gene Therapy Market, By Application, 2018–2026 ($Million) Table 64. Japan Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 65. Japan Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 66. Japan Gene Therapy Market, By Application, 2018–2026 ($Million) Table 67. China Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 68. China Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 69. China Gene Therapy Market, By Application, 2018–2026 ($Million) Table 70. India Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 71. India Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 72. India Gene Therapy Market, By Application, 2018–2026 ($Million) Table 73. South Korea Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 74. South Korea Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 75. South Korea Gene Therapy Market, By Application, 2018–2026 ($Million) Table 76. Rest of Asia-Pacific Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 77. Rest of Asia-Pacific Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 78. Rest of Asia-Pacific Gene Therapy Market, By Application, 2018–2026 ($Million) Table 79. Lamea Gene Therapy Market, By Country, 2018–2026 ($Million) Table 80. Lamea Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 81. Lamea Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 82. Lamea Gene Therapy Market, By Application, 2018–2026 ($Million) Table 83. Brazil Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 84. Brazil Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 85. Brazil Gene Therapy Market, By Application, 2018–2026 ($Million) Table 86. South Africa Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 87. South Africa Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 88. South Africa Gene Therapy Market, By Application, 2018–2026 ($Million) Table 89. Rest of Lamea Gene Therapy Market, By Vector Type, 2018–2026 ($Million) Table 90. Rest of Lamea Gene Therapy Market, By Gene Type, 2018–2026 ($Million) Table 91. Rest of Lamea Gene Therapy Market, By Application, 2018–2026 ($Million) Table 92. Adaptimmune: Company Snapshot Table 93. Adaptimmune: Business Unit Table 94. Adaptimmune.: Product Portfolio Table 95. Anchiano Therapeutics: Company Snapshot Table 96. Anchiano Therapeutics: Product Category Table 97. Anchiano Therapeutics: Product Portfolio Table 98. Achieve Life Sciences.: Company Snapshot Table 99. Achieve Life Sciences.: Operating Segments Table 100. Achieve Life Sciences: Product Portfolio Table 101. Adverum Biotechnologies, Inc.: Company Snapshot Table 102. Adverum Biotechnologies, Inc.: Product Category Table 103. Adverum Biotechnologies, Inc.: Product Portfolio Table 104. Abeona Therapeutics Inc.: Company Snapshot Table 105. Abeona Therapeutics Inc.: Product Category Table 106. Abeona Therapeutics Inc.: Product Portfolio Table 107. Applied Genetic Technologies Corporation: Company Snapshot Table 108. Applied Genetic Technologies Corporation: Operating Segments Table 109. Applied Genetic Technologies Corporation: Product Portfolio Table 110. Arbutus: Company Snapshot Table 111. Arbutus: Product Portfolio Table 112. Audentes: Company Snapshot Table 113. Audentes: Product Portfolio Table 114. Avexis: Company Snapshot Table 115. Avexis: Product Portfolio Table 116. Bluebird Bio : Company Snapshot Table 117. Bluebird Bio: Product Category Table 118. Bluebird Bio.: Product Portfolio Table 119. Celgene: Company Snapshot Table 120. Celgene: Operating Segments Table 121. Celgene: Product Portfolio Table 122. Crispr: Company Snapshot Table 123. Crispr: Product Portfolio Table 124. Editas.: Company Snapshot Table 125. Editas: Product Portfolio Table 126. Gilead: Company Snapshot Table 127. Gilead: Operating Segments Table 128. Gilead: Product Portfolio Table 129. Gsk.: Company Snapshot Table 130. Gsk: Operating Segments Table 131. Gsk: Product Portfolio Table 132. Intellia: Company Snapshot Table 133. Intellia: Product Portfolio Table 134. Merck: Company Snapshot Table 135. Merck: Operating Segments Table 136. Merck.: Product Portfolio Table 137. Novartis: Company Snapshot Table 138. Novartis: Operating Division Table 139. Novartis: Product Portfolio Table 140. Regenxbio: Company Snapshot Table 141. Regenxbio: Product Portfolio Table 142. Spark Therapeutics: Company Snapshot Table 143. Spark Therapeutics, Inc.: Product Category Table 144. Spark Therapeutics, Inc.: Product Portfolio Table 145. Sangamo Therapeutics: Company Snapshot Table 146. Sangamo Therapeutics: Operating Business Segments Table 147. Sangamo Therapeutics: Product Portfolio Table 148. Uniqure: Company Snapshot Table 149. Uniqure: Product Business Segment Table 150. Uniqure.: Product Portfolio Table 151. Voyager.: Company Snapshot Table 152. Voyager : Product Business Segments Table 153. Voyager.: Product Portfolio List of Figures Figure 01. Global Gene Therapy Market Segmentation Figure 02. Top Investment Pockets: By Gene Type, 2018 Figure 03. Top Winning Strategies, By Year, 2016–2019* Figure 04. Top Winning Strategies, By Development, 2016–2019* (%) Figure 05. Top Winning Strategies, By Company, 2016–2019* Figure 06. Top Player Positioning, 2018 Figure 07. Low Bargaining Power of Buyers Figure 08. High Bargaining Power of Suppliers Figure 09. High Threat of New Entrants Figure 10. Moderate Threat of Substitution Figure 11. High Competitive Rivalry Figure 12. Restraints And Drivers: Global Gene Therapy Market Figure 13. Comparative Regional Share Analysis of Gene Therapy Market For Viral Vectors, 2018 Vs 2026 ($Million) Figure 14. Comparative Analysis of Gene Therapy Market For Non-Viral Vectors, 2018 Vs 2026 (%) Figure 15. Comparative Analysis of Antigen Gene Therapy Market, By Country, 2018 Vs 2026 (%) Figure 16. Comparative Analysis of Cytokine Gene Therapy Market, By Country, 2018 Vs 2026 (%) Figure 17. Comparative Analysis of Tumor Suppressor Gene Therapy Market, By Country, 2018 Vs 2026 (%) Figure 18. Comparative Analysis of Suicide Gene Therapy Market, By Country, 2018 Vs 2026 (%) Figure 19. Comparative Analysis of Deficiency Gene Therapy Market, By Country, 2018 Vs 2026 (%) Figure 20. Comparative Analysis of Growth Factors Gene Therapy Market, By Country, 2018 Vs 2026(%) Figure 21. Comparative Analysis of Receptors Gene Therapy Market, By Country, 2018 Vs 2026 (%) Figure 22. Comparative Analysis of Gene Therapy Market For Other Gene Types, 2018 Vs 2026 (%) Figure 23. Comparative Analysis of Gene Therapy Market For Oncological Disorders, 2018 Vs 2026 (%) Figure 24. Comparative Analysis of Gene Therapy Market For Rare Diseases, 2018 Vs 2026 (%) Figure 25. Comparative Analysis of Gene Therapy Market For Cardiovascular Diseases, 2018 Vs 2026 (%) Figure 26. Comparative Analysis of Gene Therapy Market For Neurological Disorders, 2018 Vs 2026 (%) Figure 27. Comparative Analysis of Gene Therapy Market For Infectious Diseases, 2018 Vs 2026 (%) Figure 28. Comparative Analysis of Gene Therapy Market For Other Diseases, 2018 Vs 2026 (%) Figure 29. Adaptimmune: Revenue, 2016-2018($Million) Figure 30. Adaptimmune: Segmentation, 2016-2018(%) Figure 31. Abeona Therapeutics Inc.: Net Sales, 2014–2016 ($Million) Figure 32. Applied Genetic Technologies Corporation: Net Sales, 2015–2017 ($Million) Figure 33. Arbutus: Net Sales, 2016–2018 ($Million) Figure 34. Bluebird Bio: Revenue, 2016-2018($Million) Figure 35. Celgene: Revenue, 2016-2018($Million) Figure 36. Celgene: Revenue Share By Product, 2018 (%) Figure 37. Celgene: Revenue Share By Region, 2018 (%) Figure 38. Crispr: Net Sales, 2016–2018 ($Million) Figure 39. Editas: Net Sales, 2016–2018 ($Million) Figure 40. Gilead: Revenue, 2016-2018($Million) Figure 41. Gilead: Revenue Share By Region, 2018 (%) Figure 42. Gsk: Revenue, 2016-2018($Million) Figure 43. Gsk: Revenue Share By Segment, 2018 (%) Figure 44. Gsk: Revenue Share By Region, 2018 (%) Figure 45. Intellia: Net Sales, 2016–2018 ($Million) Figure 46. Merck: Revenue, 2016-2018($Million) Figure 47. Merck: Revenue Share By Segment, 2018 (%) Figure 48. Merck: Revenue Share By Region, 2018 (%) Figure 49. Novartis: Revenue, 2016–2018 ($Million) Figure 50. Novartis: Revenue Share By Segment, 2018 (%) Figure 51. Novartis: Revenue Share By Region, 2018 (%) Figure 52. Regenxbio: Net Sales, 2016–2018 ($Million) Figure 53. Spark Therapeutics, Inc.: Revenue, 2016–2018 ($Million) Figure 54. Sangamo Therapeutics: Net Sales, 2016–2018 ($Million) Figure 55. Uniqure.: Net Sales, 2016–2018 ($Million) Figure 56. Voyager: Net Sales, 2016–2018 ($Million)
It is a well-organized procedure to carry out research. We at Market Growth Insight follow global, all-inclusive & iterative research methodology to develop our research reports. We are using both the top down as well as bottom-up approaches for partitioning and evaluating the significant aspects of the market.
It is a systematic & strategic approach for conducting a market study. Our market research methodology is based on the concept that gives a detailed description of the factors behind an observation. Let us see the detailed market research methodology.
It is the very basic stage of research the raw data is obtained and collected on a boarded front.Data is constantly filtered to ensure that only validated and authenticated sources are considered. Moreover,information is also mined from a large group of reports in our vault, as well as various reputed paid databases. It is necessary to understand the entire value chain and in order to facilitate this; we gather information from raw material suppliers, distributors as well as buyers, for extensive knowledge of the market.
The technical issues and trends are acquired from reviews, technical discussion and trade journals. Moreover, the technical data is also accumulated from intellectual property prospective, focusing on a void area and freedom of movement. The industry elements regarding drivers, restraints, pricing trends are also collected. Subsequently, the material developed contains a wide range of original and unique information that is then further cross-validated and authenticated with published sources.
Simulation models are responsible to estimate and forecast our market, and for each research, a unique model is created and customized. The data accumulated for market dynamics, innovation scene, application improvement, estimating trends is delivered into the model and analyzedsimultaneously. These components are examined on a comparative basis, and their impact on the figure of the frame is measured with the assistance of correlation, regression and time series investigation. Forecasting of the market is performed through the consolidation of economic tools, innovative examination, and industry experience along with domain expertise. Generally, economic models are utilized for short-termforecasting, technological market models are used for long-term forecasting of a market. These are based on an amalgamation of technology innovation, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to the market estimation is preferred, with key regional markets analyzed as separate entities and integration of information to get a worldwide evaluation. This is very critical for a deep knowledge of the business as well as ensuring negligible mistakes. Below mentioned are some of the parameters are considered for forecasting
Market drivers and restraints, along with their current and expected impact
Raw material scenario and supply v/s price trends
Regulatory situation and expected developments
Current capacity and expected capacity additions up to 2025
Market driving organizations
To approve our information as far as exactness and adequacy
To pick up an understanding of the present market and future desires
We dole out weights to these parameters and evaluate their market effect utilizing weighted normal examination, to infer a normal market development rate.
This is the last advance in assessing and anticipating for our reports. Thorough essential meetings are led, on up close and personal and additionally via telephone to approve our discoveries and suppositions used to get them. Interviewees are drawn closer from driving organizations over the esteem chain including providers, innovation suppliers, area specialists,and purchasers in order to guarantee an all-encompassing and fair photo of the market. Essential meetings help in information approval, as well as give basic bits of knowledge into the market, current business situation and future desires and upgrade the nature of our reports. Every one of our assessments and figure is checked through comprehensive essential research with Key Industry Participants (KIPs) which ordinarily include:
This is the closing phase in estimating and forecasting for our reports. In this stage face to face and telephonic exhaustive interviews are conducted to validate our conclusion and assumptions used to obtain the final data. The leading companies across the value chain including suppliers, technology providers, domain experts,and purchasers are approaching the interviewees to ensure a holistic and unbiased view of the market. These interviews are led over the world, with language boundaries defeat with the guide of local staff and translators. Primary interviews in information validation as well as give critical insights into the market, current business outline and future expectations upgrade the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants include
Leading market organizations
Raw material suppliers
Product dealer
Clients or Consumers
The key targets of primary research are as per the following:
To validate our data as far as exactness and adequacy
To pick up an understanding into the present market and future desires
Select License
Payment
Why Choose Us
Get from one of the finest selection of Market Research Reports.
Your payment is 100% secured with us ensuring a fair purchase.
We provide accurate research data with comparatively best prices in the market.
More than the finest 500 companies buy their research from us.
We provide responsive 24 hours a day and 365 days customer support.
Summary ICRWorld’s Serratiopeptidase market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and
Published - Feb 2021 I Price - from $2960
Summary ICRWorld’s In Vitro Diagnostics (IVD) market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue g
Published - Feb 2021 I Price - from $2960
Summary ICRWorld’s Health and Medical Simulation Products market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users drivi
Published - Feb 2021 I Price - from $2960
Summary ICRWorld’s Vinpocetine market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profi
Published - Feb 2021 I Price - from $2960
Summary ICRWorld’s Orthopedic Braces System market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue gro
Published - Feb 2021 I Price - from $2960
Summary ICRWorld’s Knee Braces market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profi
Published - Feb 2021 I Price - from $2960
